Fig. 2From: Finding an easy way to harmonize: a review of advances in clinical research and combination strategies of EZH2 inhibitorsInhibition of EZH2 improved the effect of blocking immune checkpoint. (1) In tumor cell, high level EZH2 can inhibit CD274, the transcription factor of PD-L1. Tumor cell with low expression of PD-L1 showed resistance to anti-PD-L1 therapy, which can recover the sensitivity after inhibition EZH2. (2) In iTregs, EZH2 overexpression enhances its suppression to CD8+T cells that cannot kill tumor cells. Addition of EZH2 inhibitors can restore CD8+T cells activity to enhance antitumor ability. 3) EZH2 overexpression in tumor cells inhibits the expression of MHC I, and influences the efficacy of anti-PD-1 treatment. Treatment with EZH2 inhibitor improves the efficacy of anti-PD-1 therapy.Back to article page